These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 2510657)

  • 1. [Influence of acetylation phenotype on the pharmacokinetics and pharmacodynamics data of cadralazine in normotensive subjects].
    Brunel P; Lecaillon JB; Imhof P; Menard J
    Arch Mal Coeur Vaiss; 1989 Jul; 82(7):1257-60. PubMed ID: 2510657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of acetylator status on the haemodynamic effects and pharmacokinetics of cadralazine in healthy subjects.
    Brunel P; Lecaillon JB; Guyene TT; Imhof P; Ménard J
    Br J Clin Pharmacol; 1990 May; 29(5):503-9. PubMed ID: 2190629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of an active cadralazine metabolite in plasma and blood vessels of spontaneously hypertensive rats.
    Terauchi Y; Watari S; Ishikawa S; Takeyama K; Sekine Y; Hashimoto M; Hayashi T
    Arzneimittelforschung; 1988 Feb; 38(2):237-9. PubMed ID: 3370071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic profile of the antihypertensive vasodilator cadralazine in conscious dogs.
    Dorigotti L; Ferni G; Lombroso M; Semeraro C
    Arzneimittelforschung; 1984; 34(9):984-7. PubMed ID: 6542375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing.
    Chu KM; Shieh SM; Hu OY
    Clin Pharmacol Ther; 1995 Jun; 57(6):610-21. PubMed ID: 7781260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of chronic cardiac failure with cadralazine. Short- and medium-term results].
    Gibelin P; Lloret JL; Drici M; Leborgne L; Camous JP; Mélia P; Morand P
    Arch Mal Coeur Vaiss; 1987 Feb; 80(2):199-205. PubMed ID: 3107506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment.
    Puttonen J; Kantele S; Ruck A; Ramela M; Häkkinen S; Kivikko M; Pentikäinen PJ
    J Clin Pharmacol; 2008 Apr; 48(4):445-54. PubMed ID: 18303124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of cadralazine and its hydrazino-metabolite in patients with renal impairment after repeated administration of 5 mg once daily.
    Marichal JF; Brunel P; Lecaillon JB; Godbillon J; Faller B; Brignon P; Ménard J
    Eur J Drug Metab Pharmacokinet; 1992; 17(3):213-20. PubMed ID: 1490491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic and humoral effects at rest and after head-up tilt tests during 24-hour infusion of a new nitrate ester, ITF 296, compared with ISDN and placebo in healthy volunteers: a double-blind, randomized, within-subject study.
    Sardina M; Warrington SJ; Boyce M; Johnston A; Bianchini C
    J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S80-90. PubMed ID: 8839231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of BTS 49465 on blood pressure and peripheral arteriolar and venous tone in normal volunteers.
    Cowley AJ; Wynne RD; Hampton JR
    J Hypertens Suppl; 1984 Dec; 2(3):S547-9. PubMed ID: 6599715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals.
    Sundberg S; Antila S; Scheinin H; Häyhä M; Virtanen M; Lehtonen L
    Int J Clin Pharmacol Ther; 1998 Dec; 36(12):629-35. PubMed ID: 9876999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic effects of cadralazine in hexamethonium treated and non-treated anesthetized dogs.
    Higashio T; Tsuji Y; Nakao K; Sakaguchi S; Tanaka M
    Arzneimittelforschung; 1988 Mar; 38(3):350-8. PubMed ID: 3382459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of cadralazine in hypertensive patients.
    Leonetti G; Parini J; Visconti M; Gradnik R
    Eur J Drug Metab Pharmacokinet; 1988; 13(4):295-300. PubMed ID: 3243325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive activity of a new vasodilator, cadralazine, administered alone or in combination with a beta-blocker.
    Buoninconti R; Motolese M
    Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):613-6. PubMed ID: 2867048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of pimobendan on peripheral hemodynamics].
    Peters P; Saborowski F; Kothe A
    Z Kardiol; 1989 Aug; 78(8):538-44. PubMed ID: 2678794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Non-invasive study of the role of carotid distension in the baroreflex response to the arteriolar vasodilator cadralazine in essential hypertension].
    Laurent S; London G; Safar M
    Arch Mal Coeur Vaiss; 1986 Jun; 79(6):937-41. PubMed ID: 3099714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and pharmacologic activity of a new nitrate ester, ITF 296, after intravenous administration in healthy volunteers.
    Sardina M; Love R; Mizrahi J; Monzani V; Bianchini C
    J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S72-9. PubMed ID: 8839230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and tolerability of a delayed-action vasodilator agent, cadralazine, in severe chronic cardiac failure].
    Gibelin P; Camous JP; Profit-Degoul I; Baudouy M; Morand P
    Ann Cardiol Angeiol (Paris); 1986 Feb; 35(2):111-7. PubMed ID: 3707010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study.
    Põder P; Eha J; Sundberg S; Antila S; Heinpalu M; Loogna I; Planken U; Rantanen S; Lehtonen L
    J Clin Pharmacol; 2004 Oct; 44(10):1143-50. PubMed ID: 15342615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.